FDA Import Refusal SCS-3874257-4/11/3 — AstraZeneca Pharmaceuticals LP
The FDA refused shipment SCS-3874257-4/11/3 from AstraZeneca Pharmaceuticals LP (United States) on Mar 29, 2019. The refused product falls under Drugs and Biologics — DAPAGLIFLOZIN (ANTI-DIABETIC). Cited charge: 75 This firm has 5 or more other import refusals on record.
Refusal Details
- Date
- Mar 29, 2019
- Country
- United States
- Product Category
- Drugs and Biologics
- Product Code
- 61PCY70 DAPAGLIFLOZIN (ANTI-DIABETIC)
- Charges
- 75